Insider Transactions
| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Nov 21, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
| Nov 15, 2017 | SVP, GM - Oncology | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,000 | -- | -- | |
| Nov 15, 2017 | SVP, GM - Oncology | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 17,409 | -- | -- | |
| Sep 12, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | -- | -- | |
| Sep 12, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
| Jul 25, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
| Jul 25, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
| Jul 25, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
| Jun 19, 2017 | Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 14,000 | -- | -- | |
| Jun 02, 2017 | SVP, GM - Oncology | Form 3 | Initial Statement of Beneficial Ownership of Securities | -- | -- | -- |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.